RCT | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology

Invited commentary: Treatment withdrawal in Crohn’s disease: slowly becoming clearer – The Lancet Gastroenterology & Hepatology (free registration required)

Commentary on Twitter

New research – Louis et al – Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trialhttps://t.co/T40BmgHtem#IBD #GITwitter #medtwitter pic.twitter.com/iOIbi0WowU

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 12, 2023